Abcl stock forecast.

AbCellera Biologics is no different. Shares of this biotech have climbed 6.9% year over year as of close on January 16. The stock has shot up 9.3% in the first weeks of the new year. This biotech stock went public on the NASDAQ on December 11, 2020. It would suffer a steady decline in the months that followed its initial public offering (IPO).Their ACN share price targets range from $279.00 to $410.00. On average, they anticipate the company's stock price to reach $337.26 in the next year. This suggests that the stock has a possible downside of 0.2%. View analysts price targets for ACN or view top-rated stocks among Wall Street analysts.AbCellera Biologics saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 27,470,000 shares, a drop of 1.2% from the previous total of 27,810,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting ...ABCL Earnings Date and Information. AbCellera Biologics last issued its quarterly earnings data on November 2nd, 2023. The reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.04. The business earned $6.60 million during the quarter, compared to the consensus estimate of $11.92 million.See the latest AbCellera Biologics Inc Ordinary Shares stock price (ABCL:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Get the latest stock price for AbCellera Biologics Inc. (ABCL:US), plus the latest news, recent trades, charting, insider activity, and analyst ratings.

Created with Sketch. Market Activity. Funds + ETFs. After-Hours Quotes. News + Insights. P/E & PEG Ratios. Select time range to see more trades: Nasdaq MarketSIte.

Complete AbCellera Biologics Inc. stock information by Barron's. View real-time ABCL stock price and news, along with industry-best analysis. Now, shares are making a pullback to their 21-day line, creating a high handle for that cup base, and could offer investors a new entry. ABCL stock slipped 1.5% to close at 13.36 on the stock ...Stock Price Forecast. According to 6 stock analysts, the average 12-month stock price forecast for ABCL stock stock is $22.33, which predicts an increase of …Total Valuation. ABCL has a market cap or net worth of $1.37 billion. The enterprise value is $630.32 million. Market Cap. 1.37B. Enterprise Value. 630.32M.

Get the latest AbCellera Biologics Inc (ABCL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

Key points: Despite only being released into the Australian market a few months ago, Mounjaro is in short supply. It has been approved by the TGA as a diabetes treatment but is being prescribed ...

Recursion Pharmaceuticals Inc. 6.87. -0.18. -2.55%. Get Abcellera Biologics Inc (ABCL:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $20.00 ,the lowest forecast is $10.00. The …ABCL's current lowest rank is in the Momentum metric (where it is better than 4.01% of US stocks). ABCL Stock Summary. The price/operating cash flow metric for ABCELLERA BIOLOGICS INC is higher than 98.57% of stocks in our set with a positive cash flow. ABCL's price/sales ratio is 23.26; that's higher than the P/S ratio of 95.29% of US stocks.ABCL stock recorded 16/30 (53%) green days with 5.07% price volatility over the last 30 days. Based on our AbCellera Biologics stock forecast, it's now a bad time to buy ABCL stock because it's trading 6.53% above our forecast. Disclaimer: This is not investment advice. The information provided is for general information purposes only. 1 Month Ago. -$0.12. 3 Months Ago. -$0.14. AbCellera Biologics Inc. analyst estimates, including ABCL earnings per share estimates and analyst recommendations.See the latest AbCellera Biologics Inc Ordinary Shares stock price (ABCL:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Find the latest AbCellera (NASDAQ: ABCL) stock information.

Get the latest AbCellera Biologics Inc (ABCL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Get powerful stock screeners & detailed portfolio analysis. Subscribe Now See Plans & Pricing. AbCellera Biologics stock news, updates & related news. Find out why AbCellera Biologics's (ABCL) news sentiment is 14.35% more negative in relation to stocks in the Healthcare sector.AbCellera Biologics Inc. reported earnings of -$ 0.10 per ABCL share on Nov 2, 2023. AbCellera Biologics Inc. fell short of analysts' expectations by -28.57%. Meanwhile, the company posted an EPS of -$ 0.12 last year, which is a -193.33% lower compared to the same period last year. Report Date. Nov 2, 2023.Earnings announcement* for ABC: May 02, 2023. AmerisourceBergen Corporation (Holding Co) is expected* to report earnings on 05/02/2023 before market open. The report will be for the fiscal Quarter ...AB Capital Share Price: Find the latest news on AB Capital Stock Price. Get all the information on AB Capital with historic price charts for NSE / BSE. Experts & Broker view also get the AB ...According to 16 stock analysts, the average 12-month stock price forecast for SOFI stock stock is $8.78, which predicts an increase of 12.13%. The lowest target is $3.00 and the highest is $15. On average, analysts rate SOFI stock stock as a hold.

ABCL | Complete AbCellera Biologics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.

ABCL - Cup & Handle Breakout Trade Abcellera Biologics is a biotech stock setting up in a textbook cup with handle pattern. The stock has growing institutional sponsorship as shown in the chart from MarketSmith on the chart. It also has a relative strength ranking of 97/100. Shares formed a cup with a 37% depth and have since driftAbcellera ... Jun 6, 2022 · Insiders purchased significant amount of AbCellera stock directly after Q1. See why I ABCL shares are increasingly attractive for long-term, patient investors. AbCellera Biologics (ABCL) Risk Factors. Public companies are required to disclose risks that can affect the business and impact the stock. These disclosures are known as “Risk Factors”. Companies disclose these risks in their yearly (Form 10-K), quarterly earnings (Form 10-Q), or “foreign private issuer” reports (Form 20-F).AbCellera Biologics (ABCL) Risk Factors. Public companies are required to disclose risks that can affect the business and impact the stock. These disclosures are known as “Risk Factors”. Companies disclose these risks in their yearly (Form 10-K), quarterly earnings (Form 10-Q), or “foreign private issuer” reports (Form 20-F).Nov 13. 12.44%. $57.49. Check if ABC Stock has a Buy or Sell Evaluation. ABC Stock Price (NYSE), Forecast, Predictions, Stock Analysis and AmerisourceBergen Corp (Holding Co) News.Dec 1, 2023 · https://www.abcellera.com. AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. Track AbCellera Biologics Inc (ABCL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

Find the latest AbCellera (NASDAQ: ABCL) stock information.

The 8 analysts offering 1 year price forecasts for ABCL have a max estimate of — and a min estimate of —. Analyst rating Based on 9 analysts giving stock ratings to ABCL in the past 3 months.

Get powerful stock screeners & detailed portfolio analysis. Subscribe Now See Plans & Pricing. AbCellera Biologics stock news, updates & related news. Find out why AbCellera Biologics's (ABCL) news sentiment is 14.35% more negative in relation to stocks in the Healthcare sector.Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Ownership SEC Filings Short Interest Social Media ABCL vs. SMMT, MRUS, RYZB, ARVN, IRON, AMRX, MRVI, MIRM, PCRX, and PNTFind real-time AB - AllianceBernstein Holding LP stock quotes, company profile, news and forecasts from CNN Business. According to data from CNN Money, the 8 analysts offering 12-month price forecasts for ABCL had a median target of $24.50, with a high estimate of $34.00 and a low estimate of $12.00. This median estimate represents a remarkable increase of +517.13% from the stock’s last price of $3.97.Flood threats remain in parts of the NSW south-east hammered by a severe weather system now moving into Victoria, where days of heavy rain is expected.Nov 30, 2023 · View AbCellera Biologics Inc ABCL investment & stock information. Get the latest AbCellera Biologics Inc ABCL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Recursion Pharmaceuticals Inc. 6.87. -0.18. -2.55%. Get Abcellera Biologics Inc (ABCL:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.PLTR Stock 12 Months Forecast. Based on 15 Wall Street analysts offering 12 month price targets for Palantir Technologies in the last 3 months. The average price target is $14.67 with a high forecast of $25.00 and a low forecast of $5.00. The average price target represents a -23.59% change from the last price of $19.20.Abcellera Biologics earnings beat by $0.11, revenue fell short of estimates. By Investing.com. • Aug 03, 2023. Investing.com - Abcellera Biologics (NASDAQ: ABCL) reported second quarter EPS of ...AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -1,100% and 62.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for ...About the AbCellera Biologics Inc stock forecast. As of 2023 November 28, Tuesday current price of ABCL stock is 4.530$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).

The above table shows the analyst ABCL forecast and predictions for the stock price in 12 month’s time. Date Share Price Average 1Y Price Target Dispersion High Low 1Y Actual price Analysts; Current: US$4.83According to our current ABC stock forecast, the value of AmerisourceBergen shares will rise by 0.00% and reach $ 179.98 per share by November 22, 2023. According to our technical indicators, the current …Analyst Recommendations on AbCellera Biologics Inc. Piper Sandler Assumes AbCellera Biologics at Overweight With $20 Price Target. Oct. 13. MT. Benchmark Adjusts AbCellera Biologics' Price Target to $12 From $20, Keeps Buy Rating. Aug. 31. MT. Goldman Sachs Adjusts AbCellera Biologics' Price Target to $24 From $27, Keeps Buy Rating.ABCL stock recorded 16/30 (53%) green days with 5.07% price volatility over the last 30 days. Based on our AbCellera Biologics stock forecast, it's now a bad time to buy ABCL stock because it's trading 6.53% above our forecast. Disclaimer: This is not investment advice. The information provided is for general information purposes only.Instagram:https://instagram. 840iprinicipal retirementoffice depot tickerhow much is a silver bar worth 2023 VIE : 53.01 (unch) AbCellera Biologics (ABCL) Q2 2023 Earnings Call Transcript Motley Fool - Fri Aug 4, 12:00AM CDT. ABCL earnings call for the period ending June 30, 2023. ABCL : 4.18 (-5.00%) AbCellera Biologics (ABCL) Q1 2023 Earnings Call Transcript Motley Fool - Thu May 4, 11:30PM CDT. etrade option tradingbest tech penny stocks Analyst Recommendations on AbCellera Biologics Inc. Piper Sandler Assumes AbCellera Biologics at Overweight With $20 Price Target. Oct. 13. MT. Benchmark Adjusts AbCellera Biologics' Price Target to $12 From $20, Keeps Buy Rating. Aug. 31. MT. Goldman Sachs Adjusts AbCellera Biologics' Price Target to $24 From $27, Keeps Buy Rating.Find the latest AbCellera Biologics Inc. ABCL analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. investment rating. best rental property insurance in florida ADMA Stock 12 Months Forecast. $6.00. (51.90% Upside) Based on 2 Wall Street analysts offering 12 month price targets for ADMA Biologics in the last 3 months. The average price target is $6.00 with a high forecast of $7.00 and a low forecast of $5.00. The average price target represents a 51.90% change from the last price of $3.95.Based on short-term price targets offered by eight analysts, the average price target for AbCellera Biologics Inc. comes to $20.75. The forecasts range from a low of …